[Market Focus] QuantaMatrix Hits Upper Price Limit on Winning National Bio Project

QuantaMatrix hit the upper price limit.

At 9:05 a.m. on July 14, QuantaMatrix surged by 30% (1,050 won) from the previous trading day, reaching the upper price limit of 4,550 won. Investor sentiment was boosted following last week’s announcement that the company had been selected for the "2025 Bio Industry Technology Development (R&D) Project," organized by the Ministry of Trade, Industry and Energy and the Korea Institute for Advancement of Technology.

The total research funding for the project is approximately 7.1 billion won, of which 5.7 billion won will be provided by the government. The research task is to develop a "multimodal on-site diagnostic system for rapid identification of infectious bacteria and antibiotic susceptibility testing." QuantaMatrix will lead the project, with Seoul National University Hospital, Seoul National University Industry-Academic Cooperation Foundation, and the Korea Electronics Technology Institute participating. The goal is to develop an artificial intelligence (AI)-based automated diagnostic system (uRAST) that can quickly identify the causative bacteria and assess antibiotic susceptibility using a small amount of blood.

QuantaMatrix stated that this technology is expected to dramatically reduce the current test time, which typically takes three to four days, thereby enabling early treatment for sepsis patients.